InvestSMART

Proteomics International Laboratories Ltd (ASX: PIQ) - Announcements

Current share price for PIQ : $0.175 0.025 (12.50%)+

ASX company news and announcements for Proteomics International Laboratories Ltd (PIQ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Proteomics International Laboratories Ltd (PIQ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Proteomics International Laboratories Ltd (PIQ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Proteomics International Laboratories Ltd (PIQ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$29 Response to ASX Price Query 3 Jul 2026 5:28PM $0.200 $0.175 fallen by 12.50%
$29 Change of Registered Office Address 2 Jul 2026 11:52AM $0.143 $0.175 risen by 22.81%
$29 Application for Quotation of Securities - PIQ 3 Jun 2026 9:59AM $0.140 $0.175 risen by 25%
$29 Response to ASX Price Query 7 May 2026 1:18PM $0.185 $0.175 fallen by 5.41%
$29 Notification of Expiry of Listed Options - PIQO 1 May 2026 10:07AM $0.235 $0.175 fallen by 25.53%
$29 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 9:13AM $0.265 $0.175 fallen by 33.96%
$29 Proteomics Strategic Plan 28 Apr 2026 8:59AM $0.265 $0.175 fallen by 33.96%
$29 Final Director's Interest Notice 17 Apr 2026 2:37PM $0.260 $0.175 fallen by 32.69%
$29 Restructure, Executive Appointment and Board Update 17 Apr 2026 9:21AM $0.250 $0.175 fallen by 30%
$29 Appendix 4D and Interim Financial Report 25 Feb 2026 8:43AM $0.355 $0.175 fallen by 50.70%
$29 Final Director's Interest Notice 23 Feb 2026 4:32PM $0.365 $0.175 fallen by 52.05%
$29 Resignation of Joint Company Secretary 5 Feb 2026 9:11AM $0.490 $0.175 fallen by 64.29%
$29 Application for quotation of securities - PIQ 2 Feb 2026 10:42AM $0.520 $0.175 fallen by 66.35%
$29 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 8:25AM $0.570 $0.175 fallen by 69.30%
$29 Application for quotation of securities - PIQ 21 Jan 2026 3:30PM $0.720 $0.175 fallen by 75.69%
$29 Initial Director's Interest Notice 19 Jan 2026 10:05AM $0.815 $0.175 fallen by 78.53%
$29 Canadian patent secured for PromarkerEso test for EAC 16 Jan 2026 8:22AM $0.775 $0.175 fallen by 77.42%
$29 Application for quotation of securities - PIQ 16 Jan 2026 8:20AM $0.775 $0.175 fallen by 77.42%
$29 Appointment of CEO and Managing Director 14 Jan 2026 8:44AM $0.790 $0.175 fallen by 77.85%
$29 Application for quotation of securities - PIQ 12 Jan 2026 10:23AM $0.665 $0.175 fallen by 73.68%
$29 Notification of cessation of securities - PIQ 9 Jan 2026 11:08AM $0.685 $0.175 fallen by 74.45%
$29 Proteomics US lab CAP accredited - extends precision Dx lab 24 Dec 2025 10:15AM $0.525 $0.175 fallen by 66.67%
$29 Application for quotation of securities - PIQ 22 Dec 2025 8:38AM $0.510 $0.175 fallen by 65.69%
$29 US patent secured for PromarkerEso diagnostic test for EAC 17 Dec 2025 8:33AM $0.530 $0.175 fallen by 66.98%
$29 PromarkerD changes how Doctors manage DKD - study published 16 Dec 2025 8:45AM $0.480 $0.175 fallen by 63.54%

1 - 25 of 683 results

Page 1 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.